Navigation Links
Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:8/16/2013

inhaler (pMDI) in male and female patients diagnosed with moderate or severe COPD; 37 patients were entered into the study and 33 completed all five dosing sessions.

The primary endpoint of the study is improved lung function as measured by Forced Expiratory Volume in one second (FEV1) area under the curve from time zero to 24 hours post dose. Multiple secondary physiological (lung function) and pharmacokinetic endpoints are also being evaluated. Top-line results are expected in early 2014 and will form the basis of the future clinical development of PSX1002. For more information, see http://www.clinicaltrials.gov.

Notes for Editors

About Prosonix        http://www.prosonix.co.uk

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design.

Prosonix' ultrasonic particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products.

Prosonix' in-house pipeline focuses on near- and long-term opportunities, and is further complimented by a select number of partnered respiratory programs. The in-house pipeline includes:

  • PSX1001/PSX1050, a directly substitutable generic version of fluticasone propionate, a potent inhaled corticosteroid (ICS) monotherapy, for asthma and chronic obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI),
  • PSX2005, a directly substitutable generic version of a leading ICS/long-acting beta agonist (LABA) combination in development for asthma and COPD in pMDI,
  • PSX1002, a drug-only proprietary formulation of glycop
    '/>"/>

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
2. Accelerate Diagnostics Announces Final Results of Rights Offering
3. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
4. Accelerate Diagnostics Announces Final Terms of Rights Offering
5. Non-Toxic, Non-Surgical Medical Cancer Therapies Finally Available in the U.S.
6. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
7. Finalists Announced for Israel Brain Technologies Million Dollar Global B.R.A.I.N. Prize
8. Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results
9. Is There Finally A Way To Stop Severe Excessive Sweating?
10. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... BELMONT, Calif. , July 21, 2014 /PRNewswire/ ... world,s first fluid-based accommodating intraocular lens, today announced ... Allen, Mosbacher, and Law Chair of Ophthalmology, and ... has joined the company,s Scientific Advisory Board. ... honors, including the American Academy of Ophthalmology Lifetime ...
(Date:7/21/2014)... July 21, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that it will host a ... to discuss results for the period ended June 30, ... with respect to its clinical program for aramchol. ...
(Date:7/21/2014)...   Aventura , the leader for instant-on ... that MemorialCare Health System , a top ... at the Orange Coast Memorial Medical Center ... Orange Coast Memorial is a 218-bed general medical ... annually. The Aventura Roaming Aware Desktop (RAD) – ...
Breaking Medicine Technology:PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4Galmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 2MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 3MemorialCare Health System Launches Aventura at Orange Coast Memorial Medical Center 4
... 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today announced that ... Company's prostate cancer drug candidate CB7630,(abiraterone acetate) were ... Conference, which is currently taking place,in Lugano, Switzerland. ... presentations on Sunday, July 8, as part of ...
... Factor Xa Inhibitor,Shows a Significant Reduction in ... Enoxaparin with Similarly Low Bleeding,Rates , GENEVA, ... clinical trial,data presented today at the XXI ... demonstrate that once-daily,rivaroxaban (Xarelto®) achieved superior efficacy ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
(Date:7/22/2014)... 22, 2014 Recently, 2014quinceaneradresses.com, a popular ... its latest assortment of blue and white Quinceanera ... on these special Quinceanera gowns, hoping to show appreciation ... 30 can get a discounted price, up to 60% ... to announce these new items. As one of the ...
(Date:7/22/2014)... South Carolina (PRWEB) July 22, 2014 One ... loss solution managed to lose 20 pounds. Unfortunately, the weight ... and nauseated for the duration of her time using the ... One woman experienced heart flutters and insomnia as a result ... experienced a heart attack at the age of 37 because ...
(Date:7/22/2014)... IL (PRWEB) July 22, 2014 Hope ... of Matthew Baffoe to their Chicago staff. This addition ... Taff Construction Incorporated (TCI). Hope For The Warriors® is ... members, their families, and families of the fallen who ... of duty. , Baffoe’s work will support programs ...
(Date:7/22/2014)... Garland’s new Energizer BK specially ... as a flood coat over new and existing asphalt ... restoration material. It provides natural resistance to moisture, chemicals, ... life-cycle costs. Energizer BK is specially formulated with an ... in addition to superior strength and flexibility. , ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
Breaking Medicine News(10 mins):Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:SlimPlate System Urge Women to Shun Controversial Weight Loss Pills for Healthier Methods Like Portion Control 2Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2
... pro-health messages can predict if you,ll keep that resolution ... That,s according to a new study forthcoming in ... who were already taking action to quit," says Emily ... of the Communication Neuroscience Laboratory at the U-M Institute ...
... to develop computer-assisted diagnosis tools that will provide ... consistently accurate diagnoses. "The advent of digital ... revolution in imaging technology for histopathology," according to ... Biomedical Informatics at The Ohio State University Medical ...
... the counter has not reduced the number of teenage ... sexually-transmitted diseases (STIs), according to a report by experts ... and Sourafel Girma used local health authority data to ... to offer emergency birth control at pharmacies and without ...
... Having sex while you,re pregnant is generally safe, a new ... review authors. "There are very few proven contraindications and risks ... be reassured." The primer, based on a review of ... Medical Association Journal . Some potential, but uncommon, risks ...
... to build an extra natural layer of nanoparticle-like armour has ... startlingly simple way to give drug bearing polymer vesicles (microscopic ... The Warwick researchers have been able to decorate these ... strategy in the design of vehicles for drug release, for ...
... Scientists have discovered why orchids are one of the most ... to their relationships with the bees that pollinate them and ... the American Naturalist , is the culmination of a ... College London, the Royal Botanic Gardens, Kew, and other international ...
Cached Medicine News:Health News:Resolved to quit smoking? 2Health News:Computer-assisted diagnosis tools to aid pathologists 2Health News:Computer-assisted diagnosis tools to aid pathologists 3Health News:Morning after pill linked to increase in STIs, study shows 2Health News:Morning after pill linked to increase in STIs, study shows 3Health News:Plankton inspires creation of stealth armor for slow-release microscopic drug vehicles 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 2Health News:Wealth of orchid varieties is down to busy bees and helpful fungi, says study 3
... contain a buffered sodium citrate ... a citrate concentration of 0.109 ... (3.8%). The mixing ratio is ... 9 parts blood. In addition ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 or EDTA K3 tubes. ... therefore blocks the coagulation cascade. Erythrocytes, ... anticoagulated blood sample are stable for ... are for the examination of whole ...
Medicine Products: